Skip to main content
  • World Health Organization Global
  • Regions
    World Health Organization WHO Regional websites
    • Africa Africa
    • Americas Americas
    • South-East Asia South-East Asia
    • Europe Europe
    • Eastern Mediterranean Eastern Mediterranean
    • Western Pacific Western Pacific
  • Countries
    World Health Organization Countries in the WHO South-East Asia Region:
    • Bangladesh Bangladesh
    • Bhutan Bhutan
    • Democratic People’s Republic of Korea Democratic People’s Republic of Korea
    • India India
    • Maldives Maldives
    • Myanmar Myanmar
    • Nepal Nepal
    • Sri Lanka Sri Lanka
    • Thailand Thailand
    • Timor-Leste Timor-Leste
World Health Organization emblem
South-East Asia
Timor-Leste
  • Home
  • Health topics
  • News
  • Our work
  • Emergencies
  • About us
  1. Home /
  2. Publications /
  3. i /
  4. item /
  5. Prevention and treatment of respiratory syncytial virus disease among children: study design optimization workshop, meeting report, 9, 24 and 25 June and 7 October 2026

Prevention and treatment of respiratory syncytial virus disease among children: study design optimization workshop, meeting report, 9, 24 and 25 June and 7 October 2026

18 November 2026
 | Publication
Prevention and treatment of respiratory syncytial virus disease among children: study design optimization workshop, meeting report, 9, 24 and 25 June and 7 October 2026
Download (1.4 MB)

Overview

Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness and mortality among young children, particularly in low- and middle-income countries. Following the WHO-led paediatric drug optimization (PADO) process for RSV, WHO convened a series of technical consultations between June and October 2026 to align approaches to evidence generation for RSV prevention and treatment in children. The consultations examined regulatory requirements, clinical trial designs and key endpoints for novel RSV monoclonal antibodies and antiviral agents in an evolving prevention landscape.

The report identifies priorities for efficient, pragmatic trials, including clinically meaningful endpoints, appropriate comparators, and the use of evidence extrapolation and pharmacokinetic and safety bridging to streamline regulatory pathways. For antiviral trials, particular emphasis is placed on disease progression outcomes, early treatment and standardized core outcome measures. Participants highlighted the importance of regulatory alignment, ethically appropriate study designs and greater inclusion of low- and middle-income countries. Integrating equitable access and implementation considerations into product development is emphasized to support regulatory decisions, policy recommendations and wider availability of RSV prevention and treatment.

WHO Team
GAP-F
Editors
World Health Organization
Number of pages
27
Reference numbers
WHO Reference Number: B09982
Copyright
  • Quick links
    • Media centre
    • Head of WHO Office
  • Regional links
    • Data
    • Publications
  • Help
    • Contact us
    • Integrity Hotline
World Health Organization, Timor-Leste country office logo
Privacy Legal Notice
© 2026
WHO